Stock NOVNEE NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novartis AG Swiss Exchange

Equities

NOVNEE

CH0038459415

Pharmaceuticals

Market Closed - Swiss Exchange
Other stock markets
 11:31:41 2024-07-11 am EDT 		5-day change 1st Jan Change
99.59 CHF +1.28% Intraday chart for Novartis AG +2.25% +17.76%
Jul. 11 Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected MT
Jul. 11 Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 214,715 215,682 196,476 194,400 207,226 226,582 - -
Enterprise Value (EV) 1 230,615 240,182 204,667 203,434 219,237 239,872 238,203 232,177
P/E ratio 30.4 x 26.7 x 8.2 x 28.3 x 14.1 x 21.3 x 18.4 x 17 x
Yield 3.19% 3.56% 3.83% 3.87% 3.79% 3.31% 3.43% 3.65%
Capitalization / Revenue 4.53 x 4.43 x 3.81 x 3.85 x 4.56 x 4.6 x 4.41 x 4.35 x
EV / Revenue 4.86 x 4.94 x 3.96 x 4.02 x 4.82 x 4.87 x 4.64 x 4.46 x
EV / EBITDA 14.6 x 14.3 x 11.2 x 10.9 x 12.2 x 12.3 x 11.4 x 10.7 x
EV / FCF 17.9 x 20.5 x 15.4 x 17 x 16.6 x 17.1 x 15.2 x 14.1 x
FCF Yield 5.58% 4.87% 6.49% 5.87% 6.01% 5.86% 6.58% 7.11%
Price to Book 3.87 x 3.78 x 2.9 x 3.23 x 4.42 x 4.97 x 4.96 x 4.63 x
Nbr of stocks (in thousands) 2,264,608 2,274,506 2,237,092 2,150,980 2,055,460 2,040,406 - -
Reference price 2 94.81 94.83 87.83 90.38 100.8 111.0 111.0 111.0
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 47,445 48,659 51,626 50,545 45,440 49,243 51,390 52,100
EBITDA 1 15,809 16,845 18,246 18,613 17,937 19,432 20,963 21,619
EBIT 1 14,112 15,416 16,588 16,665 16,372 18,305 19,470 19,999
Operating Margin 29.74% 31.68% 32.13% 32.97% 36.03% 37.17% 37.89% 38.38%
Earnings before Tax (EBT) 1 8,940 9,878 26,137 8,371 9,123 13,307 14,747 15,753
Net income 1 7,147 8,072 24,021 6,955 14,854 10,727 12,021 13,047
Net margin 15.06% 16.59% 46.53% 13.76% 32.69% 21.78% 23.39% 25.04%
EPS 2 3.120 3.550 10.71 3.190 7.150 5.223 6.049 6.530
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 14,046 15,682 16,518
FCF margin 27.14% 24.03% 25.73% 23.63% 29% 28.52% 30.52% 31.7%
FCF Conversion (EBITDA) 81.44% 69.4% 72.79% 64.18% 73.47% 72.28% 74.81% 76.41%
FCF Conversion (Net income) 180.15% 144.83% 55.29% 171.75% 88.72% 130.94% 130.45% 126.6%
Dividend per Share 2 3.025 3.375 3.360 3.500 3.823 3.678 3.814 4.056
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 13,229 12,531 12,781 12,543 12,690 12,953 13,622 11,782 11,423 11,829 12,293 12,426 12,555 12,260 12,510
EBITDA 4,274 4,407 4,989 4,783 4,473 - 4,668 - 4,224 - - - - - -
EBIT 1 3,819 4,083 4,270 4,282 4,030 4,413 4,668 4,405 3,821 4,537 4,651 4,762 4,487 4,980 4,920
Operating Margin 28.87% 32.58% 33.41% 34.14% 31.76% 34.07% 34.27% 37.39% 33.45% 38.35% 37.83% 38.32% 35.73% 40.62% 39.33%
Earnings before Tax (EBT) 1 16,951 2,669 2,042 1,919 1,741 2,740 2,769 1,552 2,377 3,129 3,896 3,877 3,695 - -
Net income 1 16,308 2,222 1,695 1,575 1,466 2,293 2,316 1,513 8,480 2,688 2,820 2,826 2,481 - -
Net margin 123.27% 17.73% 13.26% 12.56% 11.55% 17.7% 17% 12.84% 74.24% 22.72% 22.94% 22.74% 19.76% - -
EPS 2 7.290 1.000 0.7700 0.7300 0.6900 1.090 1.110 0.7300 4.140 1.310 1.383 1.395 1.237 - -
Dividend per Share 2 3.360 - - - 3.500 - - - 3.823 - 0.9640 0.9627 0.9627 1.028 1.028
Announcement Date 2/2/22 4/26/22 7/19/22 10/25/22 2/1/23 4/25/23 7/18/23 10/24/23 1/31/24 4/23/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,900 24,500 8,191 9,034 12,011 13,289 11,620 5,595
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.006 x 1.454 x 0.4489 x 0.4854 x 0.6696 x 0.6839 x 0.5543 x 0.2588 x
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 14,046 15,682 16,518
ROE (net income / shareholders' equity) 17.5% 23.5% 22.7% 21% 25.4% 32.7% 38.3% 38.2%
ROA (Net income/ Total Assets) 8.89% 6.45% 10.9% 10.7% 12.4% 10.5% 12.4% 14.4%
Assets 1 80,393 125,215 221,201 64,915 120,082 101,803 97,112 90,563
Book Value Per Share 2 24.50 25.10 30.30 28.00 22.80 22.40 22.40 24.00
Cash Flow per Share 2 5.880 5.950 6.670 6.480 6.910 7.790 8.450 8.740
Capex 1 2,257 1,275 1,378 1,198 1,060 1,196 1,272 1,328
Capex / Sales 4.76% 2.62% 2.67% 2.37% 2.33% 2.43% 2.48% 2.55%
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
111 USD
Average target price
112.1 USD
Spread / Average Target
+0.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.25% 846B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.56% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.49% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.30% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.64% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.15% 240B
ROCHE HOLDING AG Stock Roche Holding AG
+3.11% 224B
AMGEN INC. Stock Amgen Inc.
+12.87% 173B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. NOVNEE Stock
  5. Financials Novartis AG